Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

This is an early-phase study looking at how a drug called nab-sirolimus (an anti-cancer agent that targets cell growth pathways) behaves in the body in people with advanced solid tumors who also have moderate liver problems. Researchers want to find the right dose and understand how liver impairment affects the drug's processing. **You may be eligible if...** - You are 18 or older - You have a confirmed advanced or metastatic solid tumor (any type) - You are in reasonably good health (ECOG 0–2) - Your blood counts, kidney function, and cholesterol/triglyceride levels meet the study requirements - You may have either normal liver function or moderate liver impairment (the study has arms for each) - You are willing to use highly effective contraception if you could become pregnant **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your cholesterol or triglycerides are significantly elevated - You do not have a confirmed solid tumor diagnosis - Your overall health or organ function does not meet the study's requirements Talk to your doctor to see if this trial is right for you.